Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

Add To Watchlist

Recent & Breaking News (TSX:VRX)

Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference

PR Newswire January 3, 2018

Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

PR Newswire December 29, 2017

Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness

PR Newswire December 22, 2017

VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors

PR Newswire December 21, 2017

Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

PR Newswire December 20, 2017

Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

PR Newswire December 18, 2017

Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

PR Newswire December 15, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com December 14, 2017

Quotidian Technical Highlights on Selected Healthcare Stocks -- Quidel, PetMed Express, Valeant Pharma, and Aradigm

PR Newswire December 11, 2017

Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

PR Newswire December 7, 2017

Valeant Announces Pricing Of Private Offering Of Senior Notes

PR Newswire December 4, 2017

Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount

PR Newswire December 4, 2017

Québec Court of Appeal Greenlights Securities Class Action on behalf of Valeant Pharmaceuticals Investors

Canada NewsWire December 4, 2017

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount

PR Newswire December 4, 2017

Valeant Announces Launch Of Private Offering Of Senior Notes

PR Newswire December 4, 2017

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Benzinga.com November 30, 2017

Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

PR Newswire November 21, 2017

Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

PR Newswire November 21, 2017

TroyGould Advises Haitong International in its $190 Million Acquisition of Obagi Skincare Products Business

PR Newswire November 16, 2017

Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program

PR Newswire November 15, 2017